{"title":"The changing environment for technological innovation in health care.","authors":"C S Goodman, A C Gelijns","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>A distinguishing feature of American health care is its emphasis on advanced technology. Yet today's changing health care environment is overhauling the engine of technological innovation. The rate and direction of technological innovation are affected by a complex of supply- and demandside factors, including biomedical research, education, patent law, regulation, health care payment, tort law, and more. Some distinguishing features of technological innovation in health care are now at increased risk. Regulatory requirements and rising payment hurdles are especially challenging to small technology companies. Closer management of health care delivery and payment, particularly the standardization that may derive from practice guidelines and clamping down on payment for investigational technologies, curtails opportunities for innovation. Levels and distribution of biomedical research funding in government and industry are changing. Financial constraints are limiting the traditional roles of academic health centers in fostering innovation. Despite notable steps in recent years to lower regulatory barriers and speed approvals, especially for products for life-threatening conditions, the Food and Drug Administration is under great pressure from Congress, industry, and patients to do more. Technology gatekeeping is shifting from hundreds of thousands of physicians acting on behalf of their patients to fewer, yet more powerful, managed care organizations and health care networks. Beyond its direct effects on adoption, payment, and use of technologies, the extraordinary buying leverage of these large providers is cutting technology profit margins and heightening competition among technology companies. It is contributing to unprecedented restructuring of the pharmaceutical and medical device industries, leading to unprecedented alliances with generic product companies, health care providers, utilization review companies, and other agents. These industry changes are already having considerable effects on investment patterns and the development, adoption, and use of new technologies. Until recently, new technologies that offered the prospect for health benefit, however, marginal or unproven, were paid for with little or no regard to cost. Technical wizardry alone no longer carries the day in health care. Today's health care market increasingly demands what other markets do--measurable improvements in benefits at acceptable costs--and innovators have begun to respond accordingly. Even so, certain key venues for health care innovation are at risk.</p>","PeriodicalId":80306,"journal":{"name":"The Baxter health policy review","volume":"2 ","pages":"267-315"},"PeriodicalIF":0.0000,"publicationDate":"1996-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Baxter health policy review","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
A distinguishing feature of American health care is its emphasis on advanced technology. Yet today's changing health care environment is overhauling the engine of technological innovation. The rate and direction of technological innovation are affected by a complex of supply- and demandside factors, including biomedical research, education, patent law, regulation, health care payment, tort law, and more. Some distinguishing features of technological innovation in health care are now at increased risk. Regulatory requirements and rising payment hurdles are especially challenging to small technology companies. Closer management of health care delivery and payment, particularly the standardization that may derive from practice guidelines and clamping down on payment for investigational technologies, curtails opportunities for innovation. Levels and distribution of biomedical research funding in government and industry are changing. Financial constraints are limiting the traditional roles of academic health centers in fostering innovation. Despite notable steps in recent years to lower regulatory barriers and speed approvals, especially for products for life-threatening conditions, the Food and Drug Administration is under great pressure from Congress, industry, and patients to do more. Technology gatekeeping is shifting from hundreds of thousands of physicians acting on behalf of their patients to fewer, yet more powerful, managed care organizations and health care networks. Beyond its direct effects on adoption, payment, and use of technologies, the extraordinary buying leverage of these large providers is cutting technology profit margins and heightening competition among technology companies. It is contributing to unprecedented restructuring of the pharmaceutical and medical device industries, leading to unprecedented alliances with generic product companies, health care providers, utilization review companies, and other agents. These industry changes are already having considerable effects on investment patterns and the development, adoption, and use of new technologies. Until recently, new technologies that offered the prospect for health benefit, however, marginal or unproven, were paid for with little or no regard to cost. Technical wizardry alone no longer carries the day in health care. Today's health care market increasingly demands what other markets do--measurable improvements in benefits at acceptable costs--and innovators have begun to respond accordingly. Even so, certain key venues for health care innovation are at risk.
美国医疗保健的一个显著特点是强调先进技术。然而,当今不断变化的医疗环境正在彻底改变技术创新的引擎。技术创新的速度和方向受到复杂的供给侧和需求侧因素的影响,包括生物医学研究、教育、专利法、法规、医疗保健支付、侵权法等等。卫生保健技术创新的一些显著特征现在面临更大的风险。对小型科技公司来说,监管要求和不断上升的支付障碍尤其具有挑战性。对保健服务的提供和支付进行更密切的管理,特别是可能源于实践准则的标准化和限制对研究技术的支付,减少了创新的机会。政府和产业界对生物医学研究的资助水平和分配正在发生变化。财政限制限制了学术卫生中心在促进创新方面的传统作用。尽管近年来在降低监管障碍和加快审批速度方面取得了显著进展,尤其是针对危及生命的疾病的产品,但美国食品和药物管理局(Food and Drug Administration)仍面临着来自国会、行业和患者的巨大压力,要求其采取更多措施。技术把关正从代表患者行事的数十万医生转向数量更少、但更强大的管理式医疗机构和医疗网络。除了对技术的采用、支付和使用产生直接影响外,这些大型供应商非凡的购买杠杆正在削减技术利润率,加剧科技公司之间的竞争。它正在促进制药和医疗器械行业前所未有的重组,导致与仿制药公司、卫生保健提供者、利用审查公司和其他代理的前所未有的联盟。这些行业变化已经对投资模式和新技术的开发、采用和使用产生了相当大的影响。直到最近,提供健康效益前景的新技术,然而,边际或未经证实,很少或根本不考虑成本。在医疗保健领域,单靠技术魔法已不再占主导地位。今天的医疗保健市场越来越需要其他市场所做的——在可接受的成本下实现可衡量的效益改进——创新者已经开始做出相应的反应。即便如此,医疗保健创新的某些关键领域仍面临风险。